Department of Haematology-Oncology, National University Cancer Institute, Singapore, 1E Lower Kent Ridge Road, Singapore, 119228, Singapore.
Department of Medicine, National University Hospital, Singapore, Singapore.
Support Care Cancer. 2021 Jul;29(7):3689-3696. doi: 10.1007/s00520-020-05872-5. Epub 2020 Nov 14.
Complementary and alternative medicine (CAM) is often used by cancer patients and is concerning as concomitant oral CAM and chemotherapy use may result in adverse interactions and toxicities. We hypothesise that a decision aid (DA) may promote informed and rational use of oral CAM during chemotherapy, and increase patients' discussion with their oncologists on CAM use.
We randomised 240 patients initiating chemotherapy to receive DA or none. Questionnaires were administered at randomisation (visit 1), 1 month (visit 2) and 3 months (visit 3). The primary endpoint was the decisional conflict score (DCS) for decision made on CAM use during chemotherapy. Secondary endpoints include patients' decision regret score (DRS) on CAM use, CAM uptake, discussion with oncologists on CAM usage, and difference in quality of life (QoL) score between CAM and non-CAM users at visit 3.
There was no difference in the mean DCS (mean difference 2.7 [95 CI - 2.9 to 8.3, p = 0.345]) and DRS (mean difference - 0.3 [95% CI - 6.3 to 5.8, p = 0.926]) between the two arms. There was a reduction in odds of CAM usage in the intervention arm compared to control arm (OR = 0.36, 95% CI 0.17 to 0.78, p = 0.009), but there was no difference in discussion with oncologists on CAM usage (OR = 0.46, 95% CI 0.07 to 3.01, p = 0.419), or in the QoL between CAM and non-CAM users.
Our DA did not reduce DCS among cancer patients on chemotherapy. DA that provides more evidence-based information on CAM, and non-judgemental discussion initiated by oncologists to discuss CAM, may improve its effectiveness.
补充和替代医学(CAM)经常被癌症患者使用,令人担忧的是,同时使用口服 CAM 和化疗可能会导致不良反应和毒性。我们假设决策辅助工具(DA)可能会促进癌症患者在化疗期间明智而理性地使用口服 CAM,并增加患者与肿瘤医生讨论 CAM 使用的情况。
我们将 240 名开始化疗的患者随机分为接受 DA 或不接受 DA 两组。在随机分组时(第 1 次就诊)、1 个月(第 2 次就诊)和 3 个月(第 3 次就诊)时进行问卷调查。主要终点是化疗期间 CAM 使用决策的决策冲突评分(DCS)。次要终点包括患者对 CAM 使用的决策后悔评分(DRS)、CAM 使用率、与肿瘤医生讨论 CAM 使用情况,以及第 3 次就诊时 CAM 和非 CAM 用户之间的生活质量(QoL)评分差异。
两组之间的平均 DCS(平均差值 2.7 [95%CI-2.9 至 8.3,p = 0.345])和 DRS(平均差值-0.3 [95%CI-6.3 至 5.8,p = 0.926])均无差异。与对照组相比,干预组使用 CAM 的可能性降低(OR = 0.36,95%CI 0.17 至 0.78,p = 0.009),但与肿瘤医生讨论 CAM 使用情况的差异无统计学意义(OR = 0.46,95%CI 0.07 至 3.01,p = 0.419),CAM 和非 CAM 用户之间的 QoL 也无差异。
我们的 DA 并未降低化疗癌症患者的 DCS。提供更多关于 CAM 的基于证据的信息,以及肿瘤医生发起的非评判性讨论来讨论 CAM,可能会提高其效果。